Sign up to save your podcasts
Or
Share Efficacy and Safety of MK-1293 Insulin Glargine Compared with Originator Insulin Glargine (Lantus) in Type 2 Diabetes (T2D)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Efficacy and Safety of MK-1293 Insulin Glargine Compared with Originator Insulin Glargine (Lantus) in Type 2 Diabetes (T2D)
Volume 2, Issue 13, Part 3.
Nestoras Mathioudakis, MD from Johns Hopkins interviews Dr. Marc Rendell from Creighton University School of Medicine about the study: Efficacy and Safety of MK-1293 Insulin Glargine Compared Along with Originator Insulin Glargine (Lantus) in Type 2 Diabetes, presented at the June 2016 American Diabetes Association Scientific Session.
The post Efficacy and Safety of MK-1293 Insulin Glargine Compared with Originator Insulin Glargine (Lantus) in Type 2 Diabetes (T2D) appeared first on DKBmed Radio.
Hosted on Acast. See acast.com/privacy for more information.
View all episodes
By eDiabetes ReviewVolume 2, Issue 13, Part 3.
Nestoras Mathioudakis, MD from Johns Hopkins interviews Dr. Marc Rendell from Creighton University School of Medicine about the study: Efficacy and Safety of MK-1293 Insulin Glargine Compared Along with Originator Insulin Glargine (Lantus) in Type 2 Diabetes, presented at the June 2016 American Diabetes Association Scientific Session.
The post Efficacy and Safety of MK-1293 Insulin Glargine Compared with Originator Insulin Glargine (Lantus) in Type 2 Diabetes (T2D) appeared first on DKBmed Radio.
Hosted on Acast. See acast.com/privacy for more information.